Skip to main content
World Today News
  • Home
  • News
  • World
  • Sport
  • Entertainment
  • Business
  • Health
  • Technology
Menu
  • Home
  • News
  • World
  • Sport
  • Entertainment
  • Business
  • Health
  • Technology
Onward Therapeutics Raises NT0 Million in Series B Financing to Advance Oncology Pipeline

Onward Therapeutics Raises NT$900 Million in Series B Financing to Advance Oncology Pipeline

November 18, 2026 Health Desk Health

Onward Therapeutics closed a NT$900 million — roughly US$28 million — Series B financing, the company announced in a press release dated Nov. 17, 2026. The money will fund its clinical cancer programs, clinical-supply manufacturing and early research.

Key Clinical Takeaways:

  • The Series B is the company’s first capital raise since it moved its global headquarters from Switzerland to Taiwan in October 2025.
  • Two clinical-stage assets anchor the pipeline: a bispecific antibody (OT-A201) in Phase 1b and an off-the-shelf natural killer cell therapy (OT-C001) being tested in France against relapsed lymphoma.
  • Preliminary responses reported by the company are early-phase observations that still require confirmation in larger trials.

First raise since the move to Taiwan

The round was raised in two closings, the second of which took place in October 2026, according to the company’s announcement. According to Pulse 2.0, this marks the first time Onward has raised capital since finishing a share exchange and relocating its worldwide headquarters from Switzerland to Taiwan in October 2025. Before that transaction, the company had raised CHF 75.5 million — approximately US$90 million — in earlier rounds, the release states.

Existing shareholders joined the round, including CDIB Capital Healthcare Ventures and Hong Kong Chlitina International. The release says the new institutional backers included Beiley Biofund, Everbright Biofund, Test Rite International, Grand Fortune Venture Capital, Hercules Bioventure Partners, MitoBitTech Venture and Top Taiwan Venture Capital, alongside participation from individual investors.

“This financing, our first since establishing our global headquarters in Taiwan, allows us to advance our clinical programs while building our R&D presence here. Many patients with difficult-to-treat or relapsed cancers still have limited treatment options. We aim to bring them new options through different types of cancer therapies,” said Dr. C. Grace Yeh, Chairperson and CEO of Onward Therapeutics, in the company’s announcement.

OT-A201: the bispecific antibody in the clinic

The larger of the two clinical-stage programs is OT-A201, a tetravalent bispecific antibody the company describes as designed to address complementary mechanisms of tumor immune evasion and potential resistance to existing therapies. In solid tumors, it has completed monotherapy dose escalation and advanced into Phase 1b, where planned work includes indication-specific expansion cohorts and combination regimens, per the release.

Onward Therapeutics Raises NT$900 Million in Series B Financing to Advance Oncology Pipeline
Photo: finance.yahoo.com

In blood cancers, the company expects to complete enrollment in a Phase 1a study by the end of 2026. The company reported preliminary tumor responses and disease stabilization across different cancer types with a manageable safety profile — framing those findings as supporting further investigation, not as confirmed efficacy.

Early-phase observations of this kind come from small dose-finding cohorts, and clinicians generally treat them as hypothesis-generating until expansion trials test a therapy in larger numbers of patients.

Pulse 2.0 noted the same framing, stating that these early observations require confirmation through additional trials.

“Our priority is to translate innovative science into meaningful clinical results. By focusing on indications where our therapies have the greatest potential to overcome treatment resistance, we aim to build a differentiated oncology pipeline to deliver new treatment options for patients,” said Dr. Armand de Gramont, President of Research and Development at Onward Therapeutics, in the company’s announcement.

OT-C001 targets refractory lymphoma patients

The second clinical-stage program, OT-C001, is an off-the-shelf, allogeneic natural killer cell therapy derived from umbilical cord blood — donor-derived cells that do not have to be engineered from an individual patient. It is being evaluated in a Phase 1 trial in France, in combination with rituximab, in patients with diffuse large B-cell lymphoma who relapsed after, or were refractory to, prior CAR-T and T-cell engager therapies, the release states.

Onward Therapeutics Raises NT$900 Million in Series B Financing to Advance Oncology Pipeline
Photo: morningstar.com

That population is difficult to treat by design: the trial enrolls people whose disease has already progressed through the standard lymphoma arsenal. The company reported a favorable preliminary safety profile and several cases of complete metabolic response, with enrollment and follow-up ongoing — an early signal the company itself presents as preliminary, pending continued follow-up.

The discovery-stage projects behind the raise

Beyond the two clinical assets, the pipeline includes two early-stage drug discovery programs described in the release: a small-molecule project in onco-metabolism, designated OT-S00X, and an antibody program targeting tumor-associated antigens, designated OT-A30X, which the company says has potential first-in-class characteristics. Proceeds also fund clinical-supply manufacturing and the company’s early-stage R&D.

What the company plans next

Onward intends to register on the Taipei Exchange’s Emerging Stock Board by the end of 2027, Pulse 2.0 and the release report. The company also plans to expand its Taiwan team and begin local clinical trials, according to Pulse 2.0.

The release states that de Gramont, who counts among the firm’s three co-founders, stepped up from Chief Scientific Officer to President of R&D in April 2026 and is responsible for guiding the company’s overall development strategy.

The two closings and the Taipei Exchange target frame the financing’s sequence: the money is largely already in hand, with the second tranche closed in October 2026, and the listing effort now sits on a dated clock. What the announcement does not say is how much of the NT$900 million is allocated to each program, or when the Phase 1b expansion cohorts in solid tumors are expected to begin.

Program Type Status per the company
OT-A201 Tetravalent bispecific antibody Phase 1b in solid tumors; Phase 1a enrollment in blood cancers to complete by end of 2026
OT-C001 Allogeneic NK cell therapy from umbilical cord blood Phase 1 with rituximab in France for relapsed/refractory DLBCL
OT-S00X Small molecule, onco-metabolism Discovery stage
OT-A30X Antibody against tumor-associated antigens Discovery stage

The signal worth watching

The strongest data point in the announcement is the complete metabolic response observed in several OT-C001 patients — a lymphoma population for whom prior CAR-T and T-cell engager treatments have already failed.

As with the OT-A201 observations, both remain preliminary and come from Phase 1 trials designed mainly for safety and dosing; the next real test is the enrollment completion the company has set for the end of 2026 and the expansion work that follows it.

Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X

Keep reading

  • SK Govt and Ruling Party Agree to Force Big Tech Data Submission to Curb AI Cheating
  • Anefp Seeks to Renegotiate Spain’s Medicines Law Following Snap Election Call

Related

Search:

World Today News

World Today News is your trusted source for global journalism — breaking headlines, in-depth analysis, and reporting from around the world.

Quick Links

  • Privacy Policy
  • About Us
  • Accessibility statement
  • California Privacy Notice (CCPA/CPRA)
  • Contact
  • Cookie Policy
  • Disclaimer
  • DMCA Policy
  • Do not sell my info
  • EDITORIAL TEAM
  • Terms & Conditions

Browse by Location

  • GB
  • NZ
  • US

Connect With Us

© 2026 World Today News. All rights reserved. Your trusted global news source directory.
For contact, advertising, copyright, issues email: [email protected]

Privacy Policy Terms of Service